The trajectory of Sildenafil presents a complex case for investors in the pharmaceutical sector. While initially a tremendous success, creating billions, the intellectual property end and the subsequent arrival of cheaper competitors have significantly impacted earnings. This raises questions about the ongoing viability of related therapeutic proje